<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221399</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001103</org_study_id>
    <nct_id>NCT04221399</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetes Patients With Renal Impairment</brief_title>
  <official_title>A Single- and Multiple-Dose Clinical Study to Evaluate Pharmacokinetics and Pharmacodynamics of DWP16001 Following Oral Dose in Type 2 Diabetes Patients With Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of kidney function on pharmacokinetics and
      pharmacodynamics of DWP16001 following single and multiple oral doses in type 2 diabetes
      patients with normal kidney function and renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>on Days 1 to 4 at selected time points</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration-time curve [AUC]</measure>
    <time_frame>on Days 1 to 4 at selected time points</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine glucose (g/day)</measure>
    <time_frame>on Days -1 to 4</time_frame>
    <description>Cummulative by time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of serum glucose</measure>
    <time_frame>on Days 1 to 4 at selected time points</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>DWP16001 Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP16001 Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>Tablets, Oral, Once daily, Single dose</description>
    <arm_group_label>DWP16001 Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>Tablets, Oral, Once daily, Multiple dose</description>
    <arm_group_label>DWP16001 Multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 19 years at the time of screening test

          -  Body weight of ≥ 50.0 kg to ≤ 90.0 with a body mass index (BMI) of ≥ 20.0 to ≤ 45.0

          -  Have been diagnosed with type 2 diabetes

        Exclusion Criteria:

          -  Have clinically uncontrolled or unstable hepatic, neurological, immune system,
             respiratory, hemato-oncology, cardiovascular, or psychiatric disorder (subject with
             chronic disease such as hypertension, diabetes, and hyperlipidemia that is well
             controlled or stable is eligible to participate in the study based on investigator's
             judgement)

          -  History of gastrointestinal diseases, dialysis, kidney transplantation, HIV, hepatitis
             B or C, acute or chronic infection, recent diabetic ketoacidosis, or gastrointestinal
             surgery that may affect the absorption of the study drug

          -  Received SGLT2 inhibitors or drugs of thiazolidinedione class within 6 weeks of
             scheduled IP administration day

          -  Clinical laboratory test values are outside the accepted normal range at screening

               -  AST (SGOT), ALT (SGPT) &gt; 2 x the upper limit of normal

               -  Repeatedly confirmed QTc interval &gt; 450 ms

          -  Sitting systolic blood pressure &lt; 80 mmHg or &gt; 180 mmHg or sitting diastolic blood
             pressure &lt; 60 mmHg or &gt; 110 mmHg after resting for more than 3 minutes

          -  Other exclusive inclusion criteria, as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

